Aptinyx Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
2PO
- Latest Deal Amount
-
$30.5M
- Investors
-
2
Aptinyx General Information
Description
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Contact Information
Website
www.aptinyx.comCorporate Office
- 909 Davis Street
- Suite 600
- Evanston, IL 60201
- United States
Corporate Office
- 909 Davis Street
- Suite 600
- Evanston, IL 60201
- United States
Aptinyx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. 2PO | 13-Jan-2020 | $30.5M | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 6. IPO | 21-Jun-2018 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC (Series B) | 18-Dec-2017 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 01-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 10-May-2016 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 15-Sep-2015 | Completed | Startup | |||
| 1. Spin-Off | 28-Aug-2015 | Completed | Startup |
Aptinyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 151,772,701 | $0.010000 | $0.16 | $0.16 | 1x | $0.16 | 19.69% |
Aptinyx Comparisons
Industry
Financing
Details
Aptinyx Competitors (78)
One of Aptinyx’s 78 competitors is Climb Bio, a Formerly VC-backed company based in Wellesley Hills, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Climb Bio | Formerly VC-backed | Wellesley Hills, MA | ||||
| Neuphoria Therapeutics | Formerly VC-backed | Burlington, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom |
Aptinyx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aptinyx Patents
Aptinyx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4161517-A2 | Spiro-lactam compounds and methods of treating viral infections | Inactive | 03-Jun-2020 | ||
| CA-3184348-A1 | Spiro-lactam compounds and methods of treating viral infections using the same | Pending | 03-Jun-2020 | ||
| AU-2021284376-A1 | Spiro-lactam compounds and methods of treating viral infections | Pending | 03-Jun-2020 | ||
| US-20230210851-A1 | Spiro-lactam compounds and methods of treating viral infections using the same | Inactive | 03-Jun-2020 | ||
| AU-2020398840-A1 | Methods of treating cognitive impairment associated with neurodegenerative disease | Pending | 04-Dec-2019 | A61K31/438 |
Aptinyx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aptinyx Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| The National Institute on Aging (NIA) | Government | |||
| Northwestern University | University |
Aptinyx ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
25.2 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Healthcare
Industry
of 577
Rank
Percentile
Medical Services
Subindustry
of 100
Rank
Percentile
Aptinyx FAQs
-
When was Aptinyx founded?
Aptinyx was founded in 2015.
-
Where is Aptinyx headquartered?
Aptinyx is headquartered in Evanston, IL.
-
What is the size of Aptinyx?
Aptinyx has 12 total employees.
-
What industry is Aptinyx in?
Aptinyx’s primary industry is Drug Discovery.
-
Is Aptinyx a private or public company?
Aptinyx is a Private company.
-
What is Aptinyx’s current revenue?
The current revenue for Aptinyx is .
-
How much funding has Aptinyx raised over time?
Aptinyx has raised $268M.
-
Who are Aptinyx’s investors?
The National Institute on Aging (NIA) and Northwestern University have invested in Aptinyx.
-
Who are Aptinyx’s competitors?
Climb Bio, Neuphoria Therapeutics, CRISPR Therapeutics, Alzheon, and Orchard Therapeutics are some of the 78 competitors of Aptinyx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
